Ever since FDA’s 2009 hearings on the Internet and social media platforms, industry has been anxiously awaiting guidance from the FDA on the proper use of social media to promote approved products. With a flurry of guidances released in 2014, FDA provided significant information for makers of prescription products who want to engage in social media channels that consumers and healthcare professionals are increasingly using to access healthcare information.
This session will provide an overview of the state of FDA guidance on social media with an emphasis on explaining where FDA has provided guidance on compliant use of social media and where FDA has failed to provide guidance. Additionally, this session will discuss how you can implement and manage programs to mitigate compliance and brand risk with an emphasis on the space-limited contexts such as Google text ads that started FDA’s focus.
At the conclusion of this 90-minute session, participants will have learned:
- The current state of FDA guidance on social media
- Timing and next steps from FDA
- Settled areas of FDA guidance that are unlikely to change
- Controversial FDA positions that are likely to be revised
- Key issues of remaining uncertainty
- Risks vs. Benefits: “Selling” management on the importance of social media
- Managing your social media activities to protect your brand
- What’s worked, what hasn’t, and what’s happened as a result